Suppr超能文献

肝细胞癌肝切除患者的围手术期营养支持

Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma.

作者信息

Ziegler T R

机构信息

Emory University School of Medicine, Atlanta, GA, USA.

出版信息

JPEN J Parenter Enteral Nutr. 1996 Jan-Feb;20(1):91-2. doi: 10.1177/014860719602000191.

Abstract

This prospective, randomized, controlled trial from the University of Hong Kong evaluated the efficacy of perioperative parenteral nutrition (PN) in patients requiring hepatectomy for primary hepatocellular carcinoma. From September 1990 through June 1993, 150 consecutive patients with resectable hepatocellular carcinoma were randomly assigned to receive either perioperative PN (n = 75), in addition to usual oral diet, or to no additional therapy (oral diet alone without PN; n = 75). Excluding patients with metastatic disease, a total of 64 patients in the perioperative PN group (39 with associated cirrhosis, 18 with chronic active hepatitis, and 7 without associated liver disease) were compared to 60 control patients (33 with cirrhosis, 12 with chronic active hepatitis and 15 with no associated liver disease). PN was started 7 days before hepatic resection and continued for 7 days after operation in the experimental patients. The PN consisted of standard micronutrients, dextrose, lipid emulsion (containing 50 percent of lipid as medium-chain triglycerides, MCT) and amino acids enriched in branched-chain amino acids (BCAA, 35 percent of PN protein intake), and provided = 1.5 g protein/kg/day and 30 kcal/kg/day. PN was administered via a superior vena cava Broviac catheter cycled over 12 hours each evening preoperatively, and as a 24 hour infusion during the postoperative week. Control patients received only 5 percent dextrose in normal saline postoperatively, with volume and sodium content similar to the experimental PN-treated patients. All patients studied (experimental and control) received 25 grams of albumin intravenously for 5 days postoperatively, and all were allowed to consume enteral diet as tolerated throughout the entire study period. Preoperative assessment included standard anthropometric indices, serum chemistries and proteins, indocyanine green clearance (an index of hepatic function), hand grip strength, and immune function tests (serum immunoglobulin concentrations and peripheral lymphocyte stimulation by phytohemagglutinin). Postoperative assessment included the same preoperative indices (chemistries measured from days 1 to 8 post-operatively), and overall postoperative mortality and morbidity during the hospitalization. Morbidity indices included both infectious complications and non-infectious complications (eg, pleural effusion, ascites, renal failure, hepatic coma). The two groups of patients were similar in age, sex, total and percent weight loss, hepatic carcinoma stage, incidence of cirrhosis, and other preoperative indices. However, a higher percentage of patients in the PN group had abnormal preoperative hepatic function by indocyanine green clearance (67 vs 47%, p = 0.03). The proportion undergoing major hepatectomy and other important intraoperative factors were similar between groups. No significant difference in postoperative hospital mortality occurred between groups (PN 8% vs control 15%; p = 0.30), and PN use did not change hand-grip strength, skin-fold thickness or midarm circumference. However, a significant beneficial effect of PN on hospital morbidity was observed Perioperative PN use was associated with a significant reduction in the overall postoperative morbidity rate (PN group 34% vs control group 55%; p = 0.02). This difference was mainly due to a significant reduction in infectious complications (PN 17% vs control 37%; p = 0.01), and in the need for diuretic drugs to control ascites (PN 25% vs control 50%; p = 0.004). There were no differences between groups in serum immunoglobulins or lymphocyte response to mitogens. There was less deterioration of liver function with PN as measured by the change in the rate of indocyanine green clearance (PN group -2.8% loss vs control group -4.8% loss; p = 0.05). The attenuation of hepatic function loss with PN occurred despite a significant rise in serum transaminase values from days 5 to 8 postoperatively. PN therapy was also associated with le

摘要

香港大学开展的这项前瞻性、随机、对照试验评估了围手术期肠外营养(PN)对因原发性肝细胞癌需行肝切除术患者的疗效。1990年9月至1993年6月,150例连续的可切除肝细胞癌患者被随机分为两组,一组除常规口服饮食外,接受围手术期PN(n = 75),另一组不接受额外治疗(仅口服饮食,不接受PN;n = 75)。排除有转移疾病的患者后,将围手术期PN组的64例患者(39例伴有肝硬化,18例患有慢性活动性肝炎,7例无相关肝脏疾病)与60例对照患者(33例肝硬化,12例慢性活动性肝炎,15例无相关肝脏疾病)进行比较。试验组患者在肝切除术前7天开始PN,并在术后持续7天。PN由标准微量营养素、葡萄糖、脂质乳剂(含50%的脂质为中链甘油三酯,MCT)和富含支链氨基酸(BCAA,占PN蛋白质摄入量的35%)的氨基酸组成,提供1.5 g蛋白质/(kg·天)和30 kcal/(kg·天)。术前每晚通过上腔静脉Broviac导管进行12小时的PN循环输注,术后一周进行24小时输注。对照患者术后仅接受5%葡萄糖生理盐水,其容量和钠含量与接受PN治疗的试验组患者相似。所有研究患者(试验组和对照组)术后均静脉输注25克白蛋白,持续5天,并且在整个研究期间均允许患者根据耐受情况食用肠内饮食。术前评估包括标准人体测量指标、血清化学指标和蛋白质、吲哚菁绿清除率(肝功能指标)、握力和免疫功能测试(血清免疫球蛋白浓度和植物血凝素刺激外周淋巴细胞)。术后评估包括相同的术前指标(术后第1至8天测量的化学指标)以及住院期间的总体术后死亡率和发病率。发病率指标包括感染性并发症和非感染性并发症(如胸腔积液、腹水、肾衰竭、肝昏迷)。两组患者在年龄、性别、总体和体重减轻百分比、肝癌分期、肝硬化发生率及其他术前指标方面相似。然而,PN组术前通过吲哚菁绿清除率评估肝功能异常的患者比例更高(67%对47%,p = 0.03)。两组间接受大肝切除术的比例和其他重要术中因素相似。两组术后医院死亡率无显著差异(PN组8%对对照组15%;p = 0.30),使用PN并未改变握力、皮褶厚度或上臂围。然而,观察到PN对医院发病率有显著有益影响。围手术期使用PN与术后总体发病率显著降低相关(PN组34%对对照组5%;p = 0.02)。这种差异主要是由于感染性并发症显著减少(PN组17%对对照组37%;p = 0.01)以及控制腹水所需利尿剂的使用减少(PN组25%对对照组50%;p = 0.004)。两组间血清免疫球蛋白或淋巴细胞对丝裂原的反应无差异。通过吲哚菁绿清除率变化测量,PN组肝功能恶化程度较轻(PN组下降2.8%,对照组下降4.8%;p = 0.05)。尽管术后第5至8天血清转氨酶值显著升高,但PN仍使肝功能损失减轻。PN治疗还与……相关

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验